Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2012

01-11-2012 | Review Article

Hepatitis B virus management to prevent reactivation after chemotherapy: a review

Authors: Jessica P. Hwang, John M. Vierling, Andrew D. Zelenetz, Susan C. Lackey, Rohit Loomba

Published in: Supportive Care in Cancer | Issue 11/2012

Login to get access

Abstract

Purpose

Reactivation of hepatitis B virus (HBV) infection after chemotherapy can lead to liver failure and death. Conflicting recommendations regarding HBV screening in cancer patients awaiting chemotherapy mean that some patients at risk for HBV reactivation are not being identified and treated with prophylactic antiviral therapy.

Methods

We performed a narrative review of the existing evidence regarding screening for and management of HBV infection among patients with cancer using Ovid Medline, PubMed, and the Cochrane Library.

Results

Our review showed inconsistencies in the definition and management strategies for HBV reactivation. The timeframe of reactivation is variable, and its molecular mechanisms are not clear. There are five effective antiviral agents that can be used as prophylaxis to prevent reactivation of HBV infection in cancer patients; however, the optimal drug and duration of therapy are unknown. Reactivation is more commonly reported in patients with hematologic malignancies receiving rituximab treatment, but reactivation can occur after other chemotherapies and in patients with solid tumors. Screening with all three screening tests—HBsAg, anti-HBc, and anti-HBs—allows the most thorough interpretation of a patient’s serologic profile and assessment of reactivation risk; however, decision-making and cost-effectiveness studies are needed to determine optimal screening strategies.

Conclusions

Prevention of reactivation of HBV infection depends on identification of patients at risk and initiation of antiviral prophylaxis, but data to guide screening and treatment strategies are lacking. Additional research is necessary to accurately define and predict reactivation, identify best antiviral treatment strategies, and identify cost-effective HBV screening strategies.
Literature
1.
Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW, Centers for Disease Control and Prevention (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:1–20PubMed
2.
3.
Institute of Medicine (2010) Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. IOM, Washington DC.
4.
Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT, Wong SL (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199–3202PubMedCrossRef
5.
6.
Tran TT, Rakoski MO, Martin P, Poordad F (2010) Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 31:240–246PubMed
7.
Lin SY, Chang ET, So SK (2007) Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 46:1034–1040PubMedCrossRef
8.
Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM (2010) Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health 1:10
9.
Brook MG, Lever AM, Kelly D, Rutter D, Trompeter RS, Griffiths P, Thomas HC (1989) Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med 71:313–317PubMed
10.
(1988) Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. MMWR Morb Mortal Wkly Rep 37: 341–6
11.
Keam B, Lee JH, Im SA, Yoon JH (2011) Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Cancer Netw 9:465–477
12.
Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ Jr (2010) Hepatitis B reactivation and rituximab in the oncology practice. Oncologist 15:1113–1121PubMedCrossRef
13.
Lee R, Vu K, Bell CM, Hicks LK (2010) Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 17:32–38PubMedCrossRef
14.
Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188PubMed
15.
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307PubMedCrossRef
16.
Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320–1328PubMedCrossRef
17.
Kohrt HE, Ouyang DL, Keeffe EB (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24:1003–1016PubMedCrossRef
18.
Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E (2011) Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 83:1909–1916PubMedCrossRef
19.
Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68–69PubMedCrossRef
20.
Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N, Onji M (2006) Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45:721–724PubMedCrossRef
21.
Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 83:1627–1631PubMedCrossRef
22.
Hsu CH, Hsu HC, Chen HL, Gao M, Yeh PY, Chen PJ, Cheng AL (2004) Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 24:3035–3040PubMed
23.
Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104–1108PubMedCrossRef
24.
25.
Wursthorn K, Wedemeyer H, Manns MP (2010) Managing HBV in patients with impaired immunity. Gut 59:1430–1445PubMedCrossRef
26.
Chou CH, Chen PJ, Jeng YM, Cheng AL, Huang LR, Cheng JC (2009) Synergistic effect of radiation and interleukin-6 on hepatitis B virus reactivation in liver through STAT3 signaling pathway. Int J Radiat Oncol Biol Phys 75:1545–1552PubMedCrossRef
27.
Alexopoulou A, Theodorou M, Dourakis SP, Karayiannis P, Sagkana E, Papanikolopoulos K, Archimandritis AJ (2006) Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations. J Viral Hepat 13:591–596PubMedCrossRef
28.
Yeo W, Zhong S, Chan PK, Ho WM, Wong HT, Chan AS, Johnson PJ (2000) Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepat 7:448–458PubMedCrossRef
29.
Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK, Leung NW, Johnson PJ (2000) Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 60:249–255PubMedCrossRef
30.
Chen PM, Yao NS, Wu CM, Yang MH, Lin YC, Hsiao LT, Yen CC, Wang WS, Fan FS, Chiou TJ, Liu JH, Lo SJ (2002) Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation. Transplantation 74:182–188PubMedCrossRef
31.
Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM (2010) Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 120:924–930PubMedCrossRef
32.
Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, Auran T, Loundou A, Motte A, Ressiot E, Norguet E, Chabannon C, Bouabdallah R, Tamalet C, Gerolami R (2010) Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 17:807–815PubMedCrossRef
33.
Alexopoulou A, Dourakis SP, Pandelidaki H, Archimandritis AJ, Karayiannis P (2006) Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol 78:1043–1046PubMedCrossRef
34.
Arraes LC, Ximenes R, Andrieu JM, Lu W, Barreto S, Pereira LM, Castelo A (2003) The biological meaning of anti-HBC positive result in blood donors: relation to HBV-DNA and to other serological markers. Rev Inst Med Trop Sao Paulo 45:137–140PubMedCrossRef
35.
Huzly D, Schenk T, Jilg W, Neumann-Haefelin D (2008) Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 46:1298–1306PubMedCrossRef
36.
Schmidt M, Nubling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK (2006) Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang 91:237–243PubMedCrossRef
37.
Miedouge M, Legrand-Abravanel F, Lalanne C, Saune K, Izopet J (2009) Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers. J Clin Virol 44:134–137PubMedCrossRef
38.
U.S. Preventive Services Task Force (2009) Screening for hepatitis B virus infection in pregnancy: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 150: 869–73
39.
Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, Cameron S, Carman W (2008) Erratum to ‘The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting’ [J. Clin. Virol. 41(4), 2008, pp. 243–254]. J Clin Virol 42:104–115PubMedCrossRef
40.
Yagci M, Ozkurt ZN, Yegin ZA, Aki Z, Sucak GT, Haznedar R (2010) Hepatitis B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematol 15:240–244CrossRef
41.
Kim YM, Jeong SH, Kim JW, Lee SH, Hwang JH, Park YS, Kim N, Lee JS, Kim HY, Lee DH (2011) Chronic hepatitis B, non-Hodgkin’s lymphoma, and effect of prophylactic antiviral therapy. J Clin Virol 51:241–245PubMedCrossRef
42.
Mya DH, Han ST, Linn YC, Hwang WY, Goh YT, Tan DC (2012) Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 23:421–426PubMedCrossRef
43.
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N (2011) Non-Hodgkin’s lymphomas. J Natl Compr Cancer Netw 9:484–560
44.
Idilman R, Arat M (2011) Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 9:641–652PubMedCrossRef
45.
Yeo W, Chan TC, Leung NWY, Lam WY, Mo FKF, Chu MT, Chan HLY, Hui EP, Lei KIK, Mok TSK, Chan PKS (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605–611PubMedCrossRef
46.
Leung C, Tsoi E, Burns G, Sievert W (2011) An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist 16:579–584PubMedCrossRef
47.
Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N (2009) Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy 1:1053–1061PubMedCrossRef
48.
Mendez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao R-X, McAfee SL, Chung RT (2011) Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 31:330–339PubMedCrossRef
49.
Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170–1180PubMedCrossRef
50.
Cil T, Altintas A, Tuzun Y, Pasa S, Isikdogan A (2007) Hepatitis B virus reactivation induced by yttrium-90-ibritumomab-tiuxetan. Leuk Lymphoma 48(9):1866–1868PubMedCrossRef
51.
Iannitto E, Minardi V, Calvaruso G, Mule A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxi A, Di Stefano R (2005) Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 74:254–258PubMedCrossRef
52.
Aomatsu T, Komatsu H, Yoden A, Hosomi A, Miyazaki H, Sogo T, Inui A, Fujisawa T, Tamai H (2010) Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin’s lymphoma in an HBV carrier. Eur J Pediatr 169:167–171PubMedCrossRef
53.
Rago A, Ridola L, Lichtner M, Mecarocci S, Marocco R, Cenfra N, Belvisi V, Mastroianni CM, Cimino G (2012) Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. J Antimicrob Chemother 67:510–511PubMedCrossRef
54.
Tapan U, May SK, Fiore J, Kozyreva O (2011) Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma. Leuk Lymphoma 52:916–918PubMedCrossRef
55.
Cortelezzi A, Vigano M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, Colombo M, Lampertico P (2006) Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1 H. J Clin Virol 35:467–469PubMedCrossRef
56.
Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, Sato Y, Maruyama Y (2006) Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 47:155–157PubMedCrossRef
57.
Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH (2011) Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 104:559–563PubMedCrossRef
58.
Yeo W, Chan PKS, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553–561PubMedCrossRef
59.
Grewal J, Dellinger CA, Yung WK (2007) Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 356:1591–1592PubMedCrossRef
60.
Eren OO, Artac M, Boruban MC, Yavas O, Arslan U, Basaranoglu M (2009) Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol 26:386–392PubMedCrossRef
61.
Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:209–220PubMedCrossRef
62.
Zhong S, Yeo W, Schroder C, Chan PK, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ (2004) High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11:55–59PubMedCrossRef
63.
Lau GK (2008) Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2:152–162PubMedCrossRef
64.
Ayoub WS, Keeffe EB (2011) Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 34:1145–1158PubMedCrossRef
65.
Kwon H, Lok AS (2011) Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8:275–284PubMed
66.
Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ (2011) Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 26:326–339PubMedCrossRef
67.
Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528PubMed
68.
Ziakas PD, Karsaliakos P, Mylonakis E (2009) Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 94:998–1005PubMedCrossRef
69.
Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R (2008) Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 15:89–102PubMed
70.
Hann HW, Gregory VL, Dixon JS, Barker KF (2008) A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B: lamivudine resistance. Hepatol Int 2:440–456PubMedCrossRef
71.
Deutsch M, Papadopoulos N, Manolakopoulos S, Hatziyanni E, Vassilopoulos D (2011) Fatal hepatitis B virus reactivation due to a lamivudine mutant despite undetectable initial viral load. Eur J Gastroenterol Hepatol 23:109PubMedCrossRef
72.
Brost S, Schnitzler P, Stremmel W, Eisenbach C (2010) Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol 16:5447–5451PubMedCrossRef
73.
Uchiyama M, Tamai Y, Ikeda T (2010) Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma. Int J Infect Dis 14:e265–e266PubMedCrossRef
74.
Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC, Lin TY (2011) Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 18:877–883PubMedCrossRef
75.
Colson P, Borentain P, Coso D, Chabannon C, Tamalet C, Gerolami R (2008) Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 143:148–150PubMedCrossRef
76.
Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H (2007) Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133:1437–1444PubMedCrossRef
77.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011–1020PubMedCrossRef
78.
Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W (2010) Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur 21:333–337
79.
Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, Sung JJ, Chan HL (2011) Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 54:236–242PubMedCrossRef
80.
Saab S, Dong MH, Joseph TA, Tong MJ (2007) Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 46:1049–1056PubMedCrossRef
81.
Day FL, Karnon J, Rischin D (2011) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29:3270–3277PubMedCrossRef
82.
Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ (2012) Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol. doi:10.​1200/​JCO.​2011.​40.​7510
83.
Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46:160–170PubMedCrossRef
84.
Ocana S, Casas ML, Buhigas I, Lledo JL (2011) Diagnostic strategy for occult hepatitis B virus infection. World J Gastroenterol 17:1553–1557PubMedCrossRef
85.
Urbani S, Fagnoni F, Missale G, Franchini M (2010) The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med 48:23–29PubMedCrossRef
86.
Shih LN, Sheu JC, Wang JT, Huang GT, Yang PM, Lee HS, Sung JL, Wang TH, Chen DS (1990) Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol 32:257–260PubMedCrossRef
87.
Wang JT, Wang TH, Sheu JC, Shih LN, Lin JT, Chen DS (1991) Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 163:397–399PubMedCrossRef
88.
Luo KX, Zhou R, He C, Liang ZS, Jiang SB (1991) Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen. J Med Virol 35:55–59PubMedCrossRef
89.
Arnold DM, Crowther MA, Meyer RM, Carruthers J, Ditomasso J, Heddle NM, McLeod A, Kelton JG (2010) Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 50:2577–2581PubMedCrossRef
90.
Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH (2012) Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 91:1007-1012
91.
Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sueoka E (2009) Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 20:2013–2017PubMedCrossRef
92.
Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST (2011) Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 90:1219-1223
93.
Wu J-M, Huang Y-H, Lee P-C, Lin H-C, Lee S-D (2009) Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 43:496–498PubMedCrossRef
94.
Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085–1089PubMedCrossRef
95.
Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, Craxi A, Di Stefano R (2009) Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int 29:1171–1177PubMedCrossRef
96.
Rossi D, Sala L, Minisini R, Fabris C, Falleti E, Cerri M, Burlone ME, Toniutto P, Gaidano G, Pirisi M (2009) Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma 50:604–611PubMedCrossRef
97.
Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S (2010) Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur J Haematol 85:243–250PubMedCrossRef
98.
Cheung W-I, Chan HL-Y, Leung VK-S, Tse C-H, Fung K, Lin S-Y, Wong A, Wong VW-S, Chau T-N (2010) Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. J Clin Virol 47:193–195PubMedCrossRef
99.
Zhang B, Wang J, Xu W, Wang L, Ni W (2010) Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis. Onkologie 33:537–539PubMedCrossRef
100.
Koo YX, Tan DS, Tan IB, Quek R, Tao M, Lim ST (2009) “Anti-HBc alone” in human immunodeficiency virus-positive and immuno-suppressed lymphoma patients. World J Gastroenterol 15:3834–3835PubMedCrossRef
101.
Hui C-K, Cheung WWW, Zhang H-Y, Au W-Y, Yueng Y-H, Leung AYH, Leung N, Luk JM, Lie AKW, Kwong Y-L, Liang R, Lau GKK (2006) Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. [Erratum appears in Gastroenterology. 2006 Oct;131(4):1363]. Gastroenterology 131:59–68PubMedCrossRef
102.
Liu CY, Chandrasekar PH, Masood A, Schiffer CA (2012) Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation. J Oncol Pharm Prac. doi:10.​1177/​1078155212447975​
103.
Larrubia JR (2011) Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol 17:1529–1530PubMedCrossRef
104.
Lim SM, Jang JW, Kim BW, Choi H, Choi KY, Park SJ, Han CW (2008) Hepatitis B virus reactivation during chlorambucil and prednisolone treatment in an HBsAg-negative and anti-HBs-positive patient with B-cell chronic lymphocytic leukemia. Korean J Hepatol 14:213–218PubMedCrossRef
105.
Senecal D, Pichon E, Dubois F, Delain M, Linassier C, Colombat P (1999) Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 24:1243–1244PubMedCrossRef
106.
Awerkiew S, Daumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH (2007) Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 38:83–86PubMedCrossRef
107.
Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, Khokhar F, Lutchman G, Kleiner DE, Young NS, Childs R, Barrett AJ, Liang TJ, Hoofnagle JH, Heller T (2009) Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 7:1130–1137PubMedCrossRef
108.
Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N (2010) Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 28:5097–5100PubMedCrossRef
109.
Strobel E, Schoniger M (2006) False-positive hepatitis serology after administration of immunoglobulins. Dtsch Med Wochenschr 131:1325–1327PubMedCrossRef
Metadata
Title
Hepatitis B virus management to prevent reactivation after chemotherapy: a review
Authors
Jessica P. Hwang
John M. Vierling
Andrew D. Zelenetz
Susan C. Lackey
Rohit Loomba
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1576-7

Other articles of this Issue 11/2012

Supportive Care in Cancer 11/2012 Go to the issue

Original Article

Pharmaceutical care for patients with breast and ovarian cancer

Original Article

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

Original Article

Impact of sildenafil on marital and sexual adjustment in patients and their wives after radiotherapy and short-term androgen suppression for prostate cancer

Original Article

A qualitative study exploring the experience of the partners of cancer survivors and their views on the role of primary care

Short Communication

High incidence of bloodstream infection detected by surveillance blood cultures in hematology patients on corticosteroid therapy

Original Article

Effect of gamma radiation on bonding to human enamel and dentin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits